| Drug General Information |
| Drug ID |
D02DPU
|
| Former ID |
DNC002665
|
| Drug Name |
Aniracetam
|
| Drug Type |
Small molecular drug
|
| Indication |
Cerebrovascular ischaemia [ICD9: 434.91; ICD10:I61-I63]
|
Approved |
[1],
[2]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C12H13NO3
|
| InChI |
InChI=1S/C12H13NO3/c1-16-10-6-4-9(5-7-10)12(15)13-8-2-3-11(13)14/h4-7H,2-3,8H2,1H3
|
| InChIKey |
ZXNRTKGTQJPIJK-UHFFFAOYSA-N
|
| CAS Number |
CAS 72432-10-1
|
| PubChem Compound ID |
|
| PubChem Substance ID |
586099, 855554, 856168, 866709, 5141621, 7848945, 7885359, 7978709, 8149895, 8151490, 11110806, 11113324, 11335578, 11360817, 11364236, 11366798, 11369360, 11372625, 11374281, 11377522, 11461789, 11491368, 11492576, 11495156, 12012619, 15195914, 17404678, 24277955, 26612390, 26746909, 26751447, 29221374, 46506607, 46530484, 47216709, 47216710, 47515250, 47736407, 47736408, 48259164, 49834898, 50039822, 50085875, 50100176, 50103913, 50103914, 53777221, 53790416, 57321194, 79402177
|
| SuperDrug ATC ID |
N06BX11
|
| Target and Pathway |
| Target(s) |
D(2) dopamine receptor |
Target Info |
Inhibitor |
[3]
|
|---|
| 5-hydroxytryptamine 2A receptor |
Target Info |
Inhibitor |
[3]
|
|
KEGG Pathway
|
Rap1 signaling pathway
|
|
cAMP signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Gap junction
|
|
Dopaminergic synapse
|
|
Parkinson's disease
|
|
Cocaine addiction
|
|
Alcoholismhsa04020:Calcium signaling pathway
|
|
Serotonergic synapse
|
|
Inflammatory mediator regulation of TRP channels
|
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Dopamine receptor mediated signaling pathway
|
|
Nicotine pharmacodynamics pathwayP04374:5HT2 type receptor mediated signaling pathway
|
|
Reactome
|
Dopamine receptors
|
|
G alpha (i) signalling eventsR-HSA-390666:Serotonin receptors
|
|
G alpha (q) signalling events
|
|
WikiPathways
|
Hypothetical Network for Drug Addiction
|
|
Monoamine GPCRs
|
|
GPCRs, Class A Rhodopsin-like
|
|
Genes and (Common) Pathways Underlying Drug Addiction
|
|
GPCR ligand binding
|
|
GPCR downstream signaling
|
|
Nicotine Activity on Dopaminergic NeuronsWP733:Serotonin Receptor 2 and STAT3 Signaling
|
|
Serotonin Receptor 2 and ELK-SRF/GATA4 signaling
|
|
SIDS Susceptibility Pathways
|
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
|
GPCRs, Other
|
| References |
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4133). |
|---|
| REF 2 | Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43. |
|---|
| REF 3 | Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43. |
|---|
